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Review Article 
The Immunology of Transplantation 
J.R. SERlE* 
ABSTRACT - A number of life-threatening diseases, such as kidney failure, diabetes, and certain kinds of 
coronary heart disease, can be cured by organ transplantation. However, despite decades of research, graft 
rejection remains a very real threat to the organ transplant recipient. In attempting to develop methods that 
interfere with the graft rejection process, scientists have uncovered a remarkably complex system of cellular 
interactions that allows the total destruction of a transplanted organ while leaving the recipient's own organs 
untouched. This ability to distinguish self from non-self is achieved through intercellular communication 
involving cell-to-cell contact and the release of a number of communication molecules. This tangled web of 
cellular interactions is the focus of a great deal of scientific interest since the solution to the graft rejection 
problem lies in our ability to understand it. In addition, the cellular interactions that produce graft rejection may 
serve as a model to help us better understand cellular communication in general. 
Introduction 
Organ transplantation is rapidly becoming a routine thera-
peutic procedure for the reversal of a number of life-
threatening diseases. Kidney transplants, the most prevalent 
and successful form of organ transplantation, now result in 
one-year graft survival rates of 70% to 80% for cadaver grafts 
and over 90% for living related donors ( 1 ). More than 200 
kidney transplants are performed each year at the University of 
Minnesota Hospitals, which have the largest and most com-
prehensive organ transplant program in the world. In addi-
tion, liver, heart, bone marrow, pancreas, lung, cornea, middle 
ear, and heart/lung transplants have been performed at this 
center and others with increasing success. Despite these 
strides, transplant patients must live with the constant threat 
that their new life-saving organ will be rejected. During the 
rejection process, the cells of the transplanted organ are rec-
ognized as foreign by the recipient's immune system and are 
subsequently attacked and destroyed. 
Under normal circumstances, it is in our best interest to 
have foreign cells eliminated from our bodies. Our constant 
temperature, electrolyte balance, and nutrient supply make us 
superior incubators for a wide variety of infectious microor-
ganisms, which would quickly invade and overcome our 
bodies without the immune system standing guard. Unfortu-
nately, the immune stystem does not use harmfulness as a 
criterion for recognition but rather foreignness. Because the 
cells of another individual are foreign, they are subject to the 
same recognition and attack as the microorganisms the 
immune system evolved to handle. 
Beyond advances in surgical techniques and organ preser-
vation, then, an integral component of transplantation therapy 
involves attempting to thwart the ability of the recipient's 
immune system to either recognize or attack the newly trans-
planted organ. Efforts in this area include donor-recipient 
matching, in which the genetic foreignness of the donor tissue 
is minimized, and the development of agents that suppress 
the recipient's immune system. Unfortunately, with a sup-
pressed immune system, the recipient becomes vulnerable to 
opportunistic infections that can be life threatening. A new 
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generation of immunosuppressants is being developed that 
attempts to suppress only those components of the immune 
system that cause graft rejection while sparing those compo-
nents that fight infection. However, these agents are not per-
fectly able to accomplish this task and are not without side 
effects. 
The real answer to the problem of rejection lies in our 
ability to better understand the process by which grafts are 
rejected. This enormously complex process remains only par-
tially understood despite four decades of research. The prob-
lem can be divided into two major questions: 
1) How does the immune system recognize trans-
planted tissue as foreign? and 
2) Once recognition has occurred, how does the 
immune system attack and destroy the foreign graft? 
Because graft rejection requires both of these processes, pre-
venting the immune system from doing either would ensure 
graft survival. 
Recognition of Transplanted Tissue as Foreign 
The immune system uses foreignness as the sole criterion 
for recognition and destruction of a cell. The effective elimina-
tion of pathogenic microorganisms requires a system that is 
capable of killing living cells. Yet, our own cells must be 
spared this destruction. Therefore, the immune system must 
be able to differentiate self from non-self This is accom-
plished by the system's inability to recognize and respond to 
any molecule that is a legitimate component of its own body. 
Thousands of proteins and other molecules are floating free in 
the body or are embedded in the outer membranes of cells. 
During fetal development, the immune system is exposed to 
these molecules and becomes unable to respond to them. 
This tolerance of self extends only to those molecules present 
during fetal life or shortly thereafter (2 ). All other molecules, if 
presented to the immune system in the right fashion, will be 
recognized as foreign and attacked. For example, since 
microorganisms have surface molecules very different from 
ours, they are easily recognized and destroyed. 
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Leukocytes 
The immune system is embodied in the white blood cells, 
called leukocytes, and closely related cells. The immune 
response is a complex set of interactions between a foreign 
molecule, called an antigen, and the leukocytes. Lympho-
cytes, macrophages, and dendritic cells are the principal leuk-
ocytes involved in the immune response to transplanted 
tissue. 
The immune response begins when a surface receptor on a 
lymphocyte combines with the antigen for which it is specific. 
Each lymphocyte has a specific type of surface receptor with a 
shape that is complementary to just one antigen. The binding 
of the surface receptor and the antigen causes the lymphocyte 
to begin rapidly dividing or proliferating. Once stimulated by 
antigen, the various types of lymphocytes can perform their 
specific roles in the process of antigen elimination. In addi-
tion, some of these lymphocytes "remember" this encounter 
and, if presented with this antigen again, respond more 
rapidly and extensively. This memory for past encounters is 
the basis for immunization against disease. 
Glycoprotein Markers 
Normally, the immune system serves us well. However, 
when an organ is transplanted, the immune system turns its 
exquisitely sensitive and deadly power to recognize and des-
troy foreignness toward the newly grafted tissue. Special gly-
coproteins on the surface of cells are the molecules by which 
the cells of the graft are recognized as foreign. Many of the 
surface proteins on human cells are identical from person to 
person. For instance, the membrane channel for sodium is 
probably the same molecule in all members of the human 
species. However, there is a set of glycoproteins present on 
most cells of the body that is unique to each individual of the 
species. These membrane markers are encoded by an area on 
chromosome 6 called the majo~ histocompatibility complex 
(MHC) (reviewed 3-5). This complex, assumed to be present 
in all mammalian species, is called the HIA region (human 
leukocyte antigens) in humans, and in the mouse - most 
often used for investigations in this area- it is called the H-2. 
In both species there are at least three extremely polymor-
phic, codominant loci within this area coding for the Class I 
antigens - membrane-bound glycoproteins that are present 
on almost all cells of the body ( 6). The Class I antigens are 
encoded by the K, D, L, and R regions in the mouse and the A, 
B, and C regions in the human (Figure 1) (7, 8). It has been 
estimated that each of these loci may have up to 100 alleles, 
making it rare for any two people to be identical at all three of 
the known human loci unless they are identical twins. 
Because the Class I antigens are on most of the cells of the 
body, transplanted tissue bears molecules that are foreign to 
the recipient's immune system. 
A second area within the major histocompatibility complex 
codes for glycoproteins that are found only on the surface of 
lymphocytes, macrophages, dendritic cells, and a limited 
number of other cells types (9-11 ). These polymorphic, 
membrane-bound glycoproteins, called Class II antigens, can 
be recognized as foreign by the recipient's immune system 
but also probably play a key role in the interactions between 
the various components of the immune system that make the 
immune response possible (12). Class II antigens are 
encoded by the I region of the mouse and the D region of the 
human (Figure 1 ). 
Foreignness, then, is present in two forms in transplanted 
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tissue. The cells of the graft itself, for instance, kidney and liver 
cells, carry foreign Class I antigens. Plus, any transplanted 
lymphocytes, macrophages, or dendritic cells bear foreign 
Class II antigens. These cells are very likely to be transplanted 
in a graft because they reside in the fluid compartment 
bathing all the cells of the body. When they are transplanted 
with a graft, they are called passenger leukocytes. 
Presentation of soluble antigen by adherent cells 
The fact that transplanted tissue is foreign to the recipient's 
immune system is only the beginning of a story that takes a 
rather complex turn at this point. It has been apparent since 
the early 1970s that foreignness alone is not enough to trigger 
an immune response. The antigen also must be presented by 
an immune system cell which, until recently, was believed to 
be the macrophage. Rosenthal, eta!., used in vitro methods to 
demonstrate that lymphocytes would not proliferate in the 
presence of soluble antigen (as opposed to membrane-
bound antigen) unless the antigen was associated with adher-
ent cells (13, 14). (Adherent cells are leukocytes that will 
adhere to glass or plastic.) It is now known that the adherent 
population, originally thought to be entirely composed of 
macrophages, also includes dendritic cells, which are proba-
bly more potent antigen presenters than macrophages ( 11, 
15). 
Further investigation ( 16, 17) revealed that the major histo-
compatibility complex plays a significant role in the presenta-
tion of soluble antigen by adherent cells in the following way: 
The immune system has memory for antigens it has encoun-
tered before. When an antigen is encountered for the first 
time, a primary response occurs in which lymphocytes 
become primed and memory is induced. When the identical 
antigen is encountered again, a secondary response occurs, 
which includes lymphocyte proliferation. A secondary 
response will produce much more proliferation if soluble 
antigen is presented in association with an adherent cell of the 
same MHC type as the one which initially presented the 
antigen. For example, if antigen is presented in association 
with a type A adherent cell in the primary response, a strong 
secondary response will occur only if that antigen is presented 
on a type A adherent cell again. If it is presented on a type B 
adherent cell, the response will be poor. In other words, the 
lymphocytes responding in this system remember not only 
the antigen but also the major histocompatibility complex 
antigens on the surface oft he cell presenting the antigen. This 
phenomenon is called MHC restriction. Current evidence 
suggests that the Class II antigens, found on the surface of 
both macrophages and dendritic cells, are the MHC products 
involved in the presentation of soluble antigen (12). 
Thus, the MHC glycoprotein membrane markers on the cell 
surface are probably involved in the presentation of antigen 
and in the interactions of the cells oft he immune system. They 
also are involved in the recognition phase of graft rejection. 
Apparently, the presence of donor Class II antigen-bearing 
dendritic cells is necessary for the recognition of foreignness 
in transplanted tissue. Evidence for this comes from a number 
of sources. One in vitro method, the mixed leukocyte reaction 
(MLR), tests the ability of lymphocytes to recognize foreign 
MHC antigens and to respond by proliferating. In this test, 
leukocytes from one individual are mixed with leukocytes 
from a second, MHC non-identical (allogeneic) individual. 
Normally each set of leukocytes would see the other as foreign 
and would proliferate. "A" would respond to "B," and "B" 
would respond to "A." To test only one ofthese responses at a 
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Figure 1. Genetic map of the major histocompatibility complex of humans and mice. The Class I antigens, present on the surface of all cells, 
are encoded by the A, B, and C regions in the human and the K, 0, L, and R regions in the mouse. The Class II antigens, found on certain cells of 
the immune system, are encoded by regions 0/0R in humans and the I region in mice. 
time, the leukocytes from individual "A" are treated with 
chemicals or irradiation to prevent their proliferation. The "A" 
cells, then, are the stimulator cells. The leukocytes from indi-
vidual "B" remain untreated and are the responders in this 
system. Recognition of the foreign MHC antigens on the stim-
ulator cells is manifested by the proliferation of the respond-
ing cells. When dendritic cells are specifically removed from 
the stimulating leukocyte population, the proliferation of the 
responding cells is significantly reduced. Further, the addition 
of a small number of stimulator dendritic cells reconstitutes 
the proliferation ( 17). 
Numerous studies in vivo indicate that if transplanted grafts 
are purged of their passenger leukocyte population, which 
includes dendritic cells, either by a pre-transplant period in 
tissue culture that is differentially toxic to leukocytes ( 18-20) 
or by direct elimination of Class II antigen-bearing cells (21 ), 
graft survival is significantly enhanced. Further, when leuko-
cytes of donor origin are injected into recipients bearing a 
surviving graft, the graft is usually subsequently rejected (22). 
Thus, the presence of donor or stimulator dendritic cells 
appears to be a prerequisite for graft rejection and MLR 
proliferation. 
It is unclear from these investigations whether the elimina-
tion of Class II antigen-bearing cells prolongs graft survival 
through the elimination of MHC incompatible Class II anti-
gens or through the elimination of the dendritic cells on 
which they reside. In studies using strains of mice which 
differed from one another only in very limited areas of the 
MHC, it was found that if the donor and recipient are Class I 
mismatched but identical at Class II, graft rejection still occurs 
(23 ). Therefore, Class II incompatibility is not necessary for 
graft rejection but the presence of cells bearing Class II anti-
gens is. These findings are consistent with previous work 
indicating the importance of Class II bearing dendritic cells in 
antigen presentation. Although the exact role played by den-
dritic cells in graft rejection is not known, because they appear 
to be essential to the graft rejection process, their elimination 
would make grafts "invisible" to immune detection while 
leaving the functioning part of the grafted tissue unharmed. 
Anti-Class II antibodies are currently available that can specifi-
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cally kill these passenger cells. 
There is another interesting twist to this story that compli-
cates matters considerably - the minor histocompatibility 
loci. The major histocompatibility complex is only one of 
many genetic regions that cause graft rejection. The minors, as 
they are called, cause a slower rejection if they are mis-
matched, but they can ultimately lead to the loss of a function-
ing graft. 
Studies indicate that the minor antigens must be presented 
in association with the major histocompatibility antigens in 
the same fashion as soluble antigen or MHC antigens (24). 
Further, researchers have found that if passenger dendritic 
cells share the major histocompatibility antigens with the graft 
but do not share the minor antigens, they can still present the 
minors as foreign and precipitate graft rejection. However, if 
the dendritic cells do not share the major histocompatibility 
antigens with the graft, they cannot present the graft's minor 
antigens and rejection does not occur (25). Therefore, if the 
removal of dendritic cells from grafts becomes a viable 
method for prolonging graft survival, it is very important that 
the donor and recipient be mismatched as far as possible. 
Once the graft is in place, recipient dendritic cells will invade 
it and take up residence in it. If they have the same MHC as the 
graft (i.e., if the donor and recipient are matched by tissue 
typing), they may be able to present the minor histocompati-
bility differences to the recipient's immune system and pre-
cipitate rejection. It would be an ironic twist if the tissue 
typing systems established to ensure the closest possible 
match between donor and recipient are used in the future to 
ensure the greatest mismatch or a mismatch at the specific 
locus responsible for antigen presentation. 
Destruction of the Transplanted Organ 
Infiltration by leukocytes 
The sequence of events that causes graft rejection begins 
with the presentation of the graft's foreign MHC antigens to 
the recipient's leukocytes, which are continually traveling 
through all the organs of the body. These stimulated leuko-
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cytes migrate to local lymph nodes where they rapidly divide 
and become capable of destroying the graft. When these 
anti-graft effector cells are released from the local lymph 
nodes into the blood, they return to the transplanted graft, 
recognize the foreign MHC antigens that originally stimulated 
their development, and destroy the graft cells bearing these 
antigens. Once in the graft, they secrete substances that cause 
a general inflammatory response in which non-specific leuk-
ocytes are attracted to the area (26). 
Consequently, graft rejection is characterized by the infiltra-
tion of the graft by leukocytes. Analysis ofthe appearance and 
surface markers of these cells has identified them as predomi-
nantly lymphocytes and macrophages. Further analysis of the 
lymphocytes reveals the presence of both major lymphocyte 
subpopulations: the B-lymphocyte (B-cell) and the T-lym-
phocyte (T-ee!!) (27). B-lymphocytes cause cellular destruc-
tion by secreting antibodies - large proteins that bind to the 
surface markers on foreign cells -marking them for destruc-
tion by macrophages. Although B-cells make antibodies 
against foreign grafted tissue (28), this antibody-mediated 
form of destruction probably plays, at most, a minor role in the 
typical graft rejection process. A now classic experiment dem-
onstrated this: When antibodies against a skin graft were 
injected into an animal bearing the graft, the antibodies did 
not cause the graft to be rejected (29). 
The T-lymphocytes found in rejecting grafts can be further 
divided into two distinct subpopulations based on the pres-
ence of specific surface markers: the T- helper (TH) cells and 
the T-cytotoxic (Tc) cells (27). The early investigations of the 
role of each ofthese cells in graft rejection involved the use of 
the mixed leukocyte reaction (MLR) described above plus an 
additional test called the CML (cell-mediated lympholysis). 
After a leukocyte population is stimulated to proliferate in an 
MLR, the cells are transferred to a dish containing target cells, 
which share the MHC antigens of the stimulator cells. Radioac-
tive chromium has been introduced into the cytoplasm of 
these target cells. If the stimulated leukocytes can kill the 
target cells, the radioactive chromium is spilled into the 
cuture medium and can be detected. If the leukocytes cannot 
kill the targets, no radioisotope is released. 
Through the use of these two tests, it was found that T-
helper cells proliferated during the MLR but were unable to 
kill target cells in the CML, while T-cytotoxic cells did not 
proliferate during the MLR but were able to kill target cells 
(30). It was also found that if T-helper cells were removed 
from the population before stimulation in the MLR, the ability 
ofT-cytotoxic cells to kill target cells in the CML was signifi-
cantly reduced (31 ). Therefore, as their name implies, T-
helper cells help T-cytotoxic cells to become capable of kil-
ling target cells. 
For a number of years the MLR and CML were seen as in 
vitro correlates of graft rejection. It was assumed that T-
cytotoxic cells actually destroyed the graft with the help of 
T-helper cells. As investigations of this system continued, an 
additional division of labor between these two cell popula-
tions became apparent. Investigators found that T-helper cells 
respond to differences in Class II antigens, and T-cytotoxic 
cells respond to differences in Class I antigens (32). It was 
hypothesized that T-helper cells were stimulated by Class II 
differences in the graft to proliferate and help the T-cytotoxic 
cells become capable of killing the graft. The T-cytotoxic cells 
required two signals for their activation: the Class I antigens 
on the surface of the stimulating cells and a signal from the 
stimulated T-helper cells. 
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Although the T-cytotoxic cells present in a rejecting graft are 
capable of killing target cells bearing the same MHC antigens 
as the graft (33 ), they are not the only killers in the population. 
Non-specific cellular destruction, especially apparent in the 
later stages of graft rejection ( 34), may be mediated by macro-
phages (35). In a type of immune reaction called a delayed-
type hypersensitivity reaction (DTH), macrophages are 
induced to become potent killers by factors secreted by T-
helper cells (or T0 n 1 cells which, to date, cannot be distin-
guished from T-helper cells). 
There is growing evidence that the delayed-type hypersen-
sitivity reaction may play a major role in graft destruction (36). 
Some of the most compelling evidence comes from studies in 
which rats and mice bearing viable MHC disparate grafts were 
deprived of their own immune systems by irradiation and 
then repopulated with T-helper cells, T-cytotoxic cells, or the 
two subsets together. Researchers found that reconstitution 
with both subsets or T-helper cells alone caused graft rejec-
tion while reconstitution with T-cytotoxic cells did not (37). 
Although we must exercise caution in interpreting these 
results (38), growing evidence indicates that the T-cytotoxic 
cell is not the only effector cell involved in graft destruction, 
and that the macrophage, activated by the T-helper cell, may 
play a major role (39, 40). 
Cellular communication 
Regardless of the mechanism, communication between the 
cells of the immune system is a necessary prerequisite for 
destruction of the graft. Dendritic cells must communicate 
with responding cells during the antigen recognition process. 
Similarly, T-helper cells must communicate with T-cytotoxic 
cells, macrophages, and even B-lymphocytes in the process 
whereby these cells become actively engaged in graft destruc-
tion. This communication probably involves some direct cell-
to-cell contact mediated by the surface glycoproteins of the 
MHC. The cells also communicate through the release of 
soluble factors which have been shown to enhance the graft 
rejection process (41). For instance, T-helper cells secrete a 
factor called interleukin-2 (IL-2), which is required to gener-
ate the killing ability of the T-cytotoxic cell. This is presumably 
because it binds to specific receptors on the T-cytotoxic cell's 
membrane, giving this cell the signal it needs to become a 
killer ( 42 ). Additional evidence indicates that the presenta-
tion of antigen by the dendritic cell induces T-cytotoxic cells 
to become responsive to interleukin-2 ( 43 ). 
The immensely complex process by which grafts are 
rejected provides an exciting model for cellular interaction in 
general. The use of cell-to-cell contact and soluble factors as a 
way of communicating may be a widespread method used by 
many types of cells in multicellular organisms. Indeed, it has 
been found that some non-immune cellular interactions 
appear to be controlled by the genes of the major histocompa-
tibilty complex or by genes that are near the complex on the 
chromosome ( 44 ). 
Summary: A Model 
A simplified outline of the process of graft rejection is 
presented in Figure 2. The process begins with the presenta-
tion of foreign MHC antigens by a stimulator cell, probably a 
dendritic cell, which bears Class I and Class II MHC antigens. 
T-helper cells, T-cytotoxic cells, and B-lymphocytes are all 
stimulated by this antigen presentation. The T-helper cell is 
stimulted by the Class II antigens, the T-cytotoxic cell by the 
Class I antigens, and the B-lymphocyte by both. Before they 

























Figure 2. A model for the cellular interactions producing graft rejec-
tion. TH = T-helper cell; Tc = T cytotoxic cell; MAC= macrophage; B = 
B lymphocyte; DEN= dendritic cell; IL 1 and IL-2 = Interleukin 1 and 
2; MAF =macrophage activating factor; BGF = B-cell growth factor; a 
=Class I surface antigens; .A. =Class II surface antigens. 
can respond, however, each needs a second signal. The T-
helper cell receives its second signal in the form of a soluble 
factor, called co-stimulator by Lafferty ( 45 ), which the den-
dritic cell secretes when the T-helper cell binds to it. This 
soluble factor is very possibly interleukin-1. Once it has 
received both signals, the T-helper cell rapidly divides and 
secretes a second soluble factor, interleukin-2. This factor 
provides the second signal to the T-cytotoxic cell, which can 
then develop the ability to kill by cell-to-cell contact cells 
bearing the original Class I antigens. 
In addition to interleukin-2, stimulated T-helper cells also 
release macrophage activating factors, which cause macro-
phages to become active, though non-specific, killers. The 
T-he! per cells also secrete B-ee!! growth factors, which cause 
stimulated B-lymphocytes to develop into cells that secrete 
antibodies. The antibodies can then bind to the Class I anti-
gens on the surface of the graft cells and mark them for 
specific destruction by an activated macrophage. 
We are just beginning to clearly define the details of these 
cellular interactions. As investigations continue and more of 
these interactions are understood, our power to interfere with 
this process without harming the graft recipient will increase 
dramatically. There is hope that we can develop procedures 
through this research that will make organ transplantation a 
Volume 51, Number 1, 1985/86 
therapeutic alternative for the treatment of many life-threat-
ening diseases. 
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